ORAL LIQUID
NEW to Australia Introducing Episil® Oral Liquid A barrier to oral pain Information for healthcare professionals Introducing episil® oral liquid
Rapid pain relief within 5 minutes1,2 Long-lasting effect for up to 8 hours1 Ready-to-use, pocket-sized, multidose pump device3 Demonstrated safety, with no systemic side effects1 Improves patients’ quality of life during cancer therapy2 Established use in 9 other countries, including the US and UK
Oral mucositis is a serious complication of cancer therapies
Oral mucositis (OM) is one of the most common and debilitating side effects of cancer therapies.4
Risk of OM by cancer therapy Risk of OM by selected targeted therapy
High-dose radiotherapy (HNC) – up to 100%5 Everolimus – up to 70%9
High-dose chemotherapy (BMT) – up to 100%6 Afatinib – 71%10
Standard chemotherapy – up to 75%7,8 Sunitinib – up to 58%11
HNC, head and neck cancers; BMT, bone marrow transplant
Advantages of effective OM pain management12,13
Increases compliance with cancer treatment Lowers rates of hospitalisation
Maintains the ability to eat, drink, swallow and speak Lessens the need for total parenteral nutrition
Prevents dehydration and malnutrition Decreases the use of opioid analgesics
Reduces weight loss Improves patients’ quality of life episil® oral liquid — an innovative solution for oral mucositis pain episil® liquid is an innovative treatment for the intraoral pain associated with OM, providing clinically demonstrated, rapid and long-lasting pain relief.1,2 episil® liquid is recommended for use in Cancer Group guidelines in both Europe and UK14,15 for the management and relief of pain in the oral cavity in oral mucositis which may be caused by chemotherapy and/or radiotherapy. Patented and award-winning technology16 episil® liquid was developed in Sweden based on the award-winning FluidCrystal® technology.16 The product contains a patented mixture of phospholipids and glycerol dioleate.16 Within minutes of administration, and in contact with only small quantities of saliva, the lipid mixture self-assembles into a protective film that strongly adheres to the oral mucosa.17 Without producing a numbing effect, episil® liquid soothes painful oral lesions.
Lipids converge upon saliva and Spheres connect and rapidly transition Technologically advanced, bioadhesive self-assemble to form spheres into a micro-thin gel matrix barrier coats, soothes and protects No known side effects episil® liquid has demonstrated good local and systemic tolerability in pre-clinical and clinical studies, and has no known risks or side effects with use.1,15
Convenient and ready to use episil® oral liquid is supplied in a convenient, pocket-sized, multidose pump device. It is ready to use and can be applied just before meals.3
Recommended dose: 1–3 pump strokes, 2–3 times per day or as needed. episil® liquid is intended for continuous use for up to 30 days.
Content: Glycerol dioleate, phosphatidylcholine (soy lecithin), ethanol,* propylene glycol, polysorbate 80 and peppermint oil.
*<100 mg of ethanol per dose (3 pump strokes)
Efficacy proven in clinical studies67.5
In a multicentre, randomised, double-blind, crossover, A large observational study involving 44 physicians and single-dose trial with 38 head and neck cancer patients more than 150 cancer patients (e.g. breast, head and undergoing radiotherapy, and with oral mucositis Grades neck, gastrointestinal and other solid cancer tumour 2–3 (World Health Organization scale), episil® liquid patients) was conducted to confirm the efficacy and provided an immediate and long-lasting reduction of safety of episil® liquid. Some of the key study results for intraoral pain.1 The effect was clinically proven with the entire patient population were that episil® liquid a 40% mean reduction in pain (Likert scale) and provided on average a 60% decrease in oral pain when a long-lasting effect for up to 8 hours. eating, swallowing or speaking, and that over 85% of patients reported improvement in their quality of life.2
8 8 80 80
7 7 59% 59% 60 60 6 6 56% 56%
5 5 0 0